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Gastrointestinal infections are a major cause of morbidity and mortality worldwide, particularly in developing countries. The
use of probiotics to prevent and treat a variety of diarrheal diseases has gained favor in recent years. Examples where probiotics
have positively impacted gastroenteritis will be highlighted. However, the overall eﬃcacy of these treatments and the mechanisms
by which probiotics ameliorate gastrointestinal infections are mostly unknown. We will discuss possible mechanisms by which
probiotics could have a beneﬁcial impact by enhancing the prevention or treatment of diarrheal diseases.
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1. INTRODUCTION
Within the microbiota, individual bacteria containing im-
portant genes may beneﬁt the host in diﬀerent ways. As
one considers the vast community of commensal microbes,
subsets of these organisms may have important physiologic
beneﬁts for the host in the context of human nutrition
and host:microbe interactions. Probiotics may stimulate
immunity, regulate immune signaling pathways, produce
antipathogenic factors, or induce the host to produce
antipathogenic factors. Probiotics may produce secreted
factors that stimulate or suppress cytokines and cell-
mediated immunity. These factors may also interfere with
key immune signaling pathways such as the NF-κBa n d
MAP kinase cascades. Probiotics may produce factors that
inhibit pathogens and other commensal bacteria, eﬀec-
tively enabling these microbes to compete eﬀectively for
nutrients in complex communities. Microbes that produce
antipathogenic factors may represent sources of novel classes
of antimicrobial compounds, and these factors may be
regulated by master regulatory genes in particular classes of
bacteria. Microbes can also regulate signaling pathways in
immune cells that result in the production of antimicrobial
factors by mammalian cells, eﬀectively resulting in remodel-
ingofintestinalcommunitiesandpreventionortreatmentof
infections.
Gastrointestinal infections are a major cause of mor-
bidity and mortality worldwide. Studies conducted in 2006
found that, globally, severe diarrhea and dehydration are
responsible each year for the death of 1,575,000 children
under the age of ﬁve. This represents 15% of the 10.5
million deaths per year of children in this age group
[1]. According to recent estimates, acute gastroenteritis
causes as many as 770,000 hospitalizations per year in
the United States [2]. Enteric pathogens include viruses
(rotaviruses, noroviruses) and bacteria such as diﬀerent
strains of pathogenic Escherichia coli, toxigenic Clostrid-
ium diﬃcile, Campylobacter jejuni,a n dVibrio cholerae.
These pathogens produce diﬀerent types of toxins that can
cause severe or life-threatening dehydration and diarrhea.
Despite medical advances in diagnosis and treatment, the
percent and number of hospitalized pediatric patients
less than 5 years of age with severe rotavirus infection
signiﬁcantly increased when a recent time period (2001–
2003) was compared to an earlier time period (1993–
1995) [3]. In addition to the typical pattern of acute
gastroenteritis, infectious agents such as enteropathogenic
E. coli (EPEC) may cause persistent, chronic diarrhea
in children lasting longer than 1 week [4]. Such persis-
tent infections may increase the risk of dehydration and
long-term morbidities. Importantly, the relative contribu-
tions of EPEC and other bacterial pathogens to disease2 Interdisciplinary Perspectives on Infectious Diseases
remains controversial to some extent. A recent study
highlighted that increased relative risk of gastrointestinal
disease in children was only demonstrable for enteric viruses
[5].
Recent studies have highlighted long-term morbidities
associatedwithgastroenteritis.Earlychildhooddiarrheapre-
disposes children to lasting disabilities, including impaired
ﬁtness, stunted growth, and impaired cognition and school
performance [6]. Along with this data, new research on
maternal and child undernutrition reported in The Lancet in
January 2008 links poor nutrition with an increased risk for
enteric infections in children. Furthermore, irritable bowel
syndrome (IBS), a costly and diﬃcult to treat condition
that aﬀects 20% of the United States population [7], has
medical costs of up to $30 billion per year, excluding
prescription and over-the-counter drug costs [8]. IBS is
precipitated by an episode of acute gastroenteritis in up to
30% of all cases in prior studies [9]. Therefore, preventing
or treating acute gastroenteritis before long-term sequelae
develop would drastically reduce hospitalizations, disability-
adjusted life years, and both direct and indirect medical
costs.
Accurate diagnosis of acute gastroenteritis is an ongoing
challenge even in sophisticated academic medical centers.
In a pediatric patient population exceeding 4,700 chil-
dren, less than 50% of stool samples that underwent
complete microbiologic evaluation yielded a speciﬁc diag-
nosis [10]. Enteric viruses represented the predominant
etiologic agents in acute gastroenteritis in children less
than 3 years of age, and bacteria caused the majority
of cases of acute gastroenteritis in children older than 3
years of age [10]. The diagnostic challenges with enteric
viruses include the relative paucity of stool-based molec-
ular or viral antigen tests and the inability to readily
culture most enteric viruses. Bacterial pathogens may be
diﬃcult to identify (such as most strains of disease-
causing E. coli) because of the lack of speciﬁc assays
for these infections. The relative insensitivity of stool-
based toxin assays for the detection of toxigenic C. diﬃcile
precludes accurate diagnosis. In a children’s hospital set-
ting, combination toxin antigen testing yielded sensitivity
below 40% in pediatric patients (J. Versalovic, unpublished
data). The introduction of new molecular assays for real-
time PCR detection of toxin genes directly in stool has
markedly improved the ability to diagnose antimicrobial-
associated diarrhea and colitis due to toxigenic C. diﬃ-
cile [11]. In addition, approximately 15–25% of cases of
antimicrobial-associated diarrhea are caused by C. diﬃ-
cile. The prevalence of antimicrobial-associated diarrhea
and gastrointestinal disease highlights the importance of
alternatives to antibiotic strategies for treatment. Further-
more, antibiotics have limited utility for the treatment
of gastroenteritis in general. Antimicrobial agents are not
generally recommended as prevention strategies because of
the problems of antibiotic resistance and antimicrobial-
associated disease. Thus, instead of suppressing bacterial
populations with antibiotics, can probiotics be used to
remodel or shift microbial communities to a healthy state
[12]?
2. PROBIOTICS
2.1. Theneedformechanisticdetailsof
probioticaction
The use of probiotics to prevent and treat a wide variety of
conditions has gained favor in the past decade. This is in part
duetoaneedtoﬁndalternativestotraditionaltherapiessuch
as antibiotics as well as the lack of good treatments for GI
ailments. While there are increasing reports of the eﬃcacy of
probiotics in the treatment of diseases such as pouchitis [13,
14],diarrhea[15–17],andirritablebowelsyndrome[18],the
scientiﬁc basis for the use of probiotics is just beginning to
be understood. We will focus on the potential applications
for probiotics in the treatment of diarrheal disease. Several
examples will highlight how probiotics may be selected for
and utilized against pathogens causing gastroenteritis.
The concept of using probiotic microorganisms to pre-
vent and treat a variety of human ailments has been around
for more than 100 years [19]. With the rise in the number
of multidrug resistant pathogens and the recognition of
the role that the human microbiota plays in health and
disease, a recent expansion in the interest in probiotics has
been generated. This phenomenon is apparent in both the
numbersofprobioticproductsbeingmarketedtoconsumers
as well as the increased amount of scientiﬁc research
occurring in probiotics. Although many of the mechanisms
by which probiotics beneﬁt human beings remain unclear,
probiotic bacteria are being utilized more commonly to treat
speciﬁc diseases.
Several deﬁnitions of what constitutes a “probiotic” in
the literature have been formulated. For this review, we use
the deﬁnition derived in 2001 by the Food and Agricultural
Organization (FAO) and the World Health Organization
(WHO)—“Probiotics are live microorganisms which when
administered in adequate amount confer a health beneﬁt
on the host.” [20]. This deﬁnition is the currently accepted
deﬁnition by the International Scientiﬁc Association for
Probiotics and Prebiotics (ISAPP) (http://www.isapp.net/).
2.2. Antipathogenicactivities
Perhaps the most important scientiﬁc question regarding
the use of probiotics in medicine is the identiﬁcation of
mechanisms by which probiotics impact human health.
Several mechanisms have been implicated but most have
not been experimentally proven (Figure 1). Here, we discuss
possible mechanisms that are relevant for the treatment of
diarrheal diseases. We will highlight research examples that
support these putative mechanisms whenever possible.
2.3. Stimulationofhostantimicrobialdefenses
Manyprobioticshavebeenshowntoproduceantipathogenic
compounds ranging from small molecules to bioactive
antimicrobial peptides. Most of these studies have focused
on the in vitro susceptibility of pathogens to products
secreted by probiotic bacteria. In most cases, the ability of an
antimicrobial compound secreted by a probiotic organism
to inhibit the growth of a pathogen in vivo has not beenR. A. Britton and J. Versalovic 3
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Figure 1: Probiotics and Beneﬁcial Eﬀects in the Intestine. Depiction of the interactions between beneﬁcial bacteria (left side), their secreted
factors, pathogens, and the intestinal mucosa (right side). Potential beneﬁcial eﬀects of probiotics are listed. Only two host cell types are
shown, intestinal epithelial cells and macrophages although other cell types including dendritic cells, lymphocytes, myoﬁbroblasts, and
neutrophils comprise the intestinal mucosa. The arrows indicate the release and possible distribution of secreted factors derived from
probiotics.
demonstrated. Conceptually, an antimicrobial compound
produced by an organism would need to be produced at a
high enough level and in the right location in the intestinal
tract to exert a strong eﬀect on a pathogen in vivo.
An elegant proof of principle for direct action of a
probiotic-produced antimicrobial against a pathogen was
recently reported by Corr et al. who demonstrated that pro-
duction of the bacteriocin Abp118 by Lactobacillus salivarius
was suﬃcient to protect mice from disease by infection
with Listeria monocytogenes [21]. To prove the action of the
bacteriocin was directly responsible for the protection of the
mice, they generated a L. salivarius strain that was unable to
produce Abp118 and showed that this mutant was incapable
of protecting against L. monocytogenes infection. Notably,
they were able to express a gene that confers immunity to
the Abp118 bacteriocin within L. monocytogenes and showed
that this strain was now resistant to the probiotic eﬀect of
L. salivarius within the mouse. This study provided clear
evidence that a probiotic-derived bacteriocin could function
directly on a pathogen in vivo.
2.4. Pathogenexclusionviaindirectmechanisms
In addition to producing antimicrobial compounds that
act directly on pathogens, probiotics may stimulate host
antimicrobial defense pathways. The intestinal tract has a
number of mechanisms for resisting the eﬀects of pathogens
including the production of defensins [22]. Defensins are
cationic antimicrobial peptides that are produced in a
number of cell types including Paneth cells in the crypts of
the small intestine and intestinal epithelial cells. A deﬁciency
in alpha-defensin production has been correlated with ileal
Crohn’s disease [23, 24]. Tissue samples from patients with
Crohn’s disease showed a lower level of alpha-defensin pro-
duction and extracts from these samples exhibited a reduced
ability to inhibit bacterial growth in vitro. Moreover, some
pathogenic bacteria have evolved mechanisms to inhibit the
production or mechanism of action of defensins (reviewed
in [25]).
Probiotics may act to stimulate defensin activity via at
least two mechanisms. First, probiotics may stimulate the
synthesisofdefensinexpression.Thishasbeendemonstrated
for human beta defensin 2 (hBD-2), whose expression is
upregulated by the presence of several probiotic bacteria via
the transcription factor NF-κB[ 26, 27]. The implication is
that probiotic strains with this capability would strengthen
intestinal defenses by increasing defensin levels. This eﬀect
is also observed with certain pathogenic bacteria and thus is
not a speciﬁc property of probiotic bacteria. Second, many
defensins are produced in a propeptide form that must be
activated via the action of proteases. One well-characterized
example is the activation of the murine defensin cryptdin
(an alpha-defensin that is produced by Paneth cells) by the
action of matrix metalloprotease 7 (MMP-7) [28]. Mice
defective for MMP-7 are more susceptible to killing by
Salmonella. Evidence indicates that bacteria can stimulate
the production of MMP-7 in the intestine [29]. Thus,
one mechanism in which probiotics could participate in
activating defensins is by stimulating the production of
MMPs in the intestinal tract. Alternatively, probiotics could4 Interdisciplinary Perspectives on Infectious Diseases
produce proteases that themselves activate defensins in
the intestinal lumen. Although there is no evidence yet
to support this mechanism, a subset of lactobacilli and
streptococci encode MMP-like proteins in their genomes
(R. Britton, unpublished observation). These MMPs are not
found in any other bacteria and thus it will be interesting to
determine what eﬀect they have on host cell function.
2.5. Immunomodulation
Rather than directly inhibiting the growth or viability of the
pathogen, probiotics may compete for an ecological niche
or, otherwise, create conditions that are unfavorable for
the pathogen to take hold in the intestinal tract. There are
many possible mechanisms for how pathogen exclusion may
take place. First, several probiotics have been demonstrated
to alter the ability of pathogens to adhere to or invade
colonic epithelial cells in vitro, for example, see [30, 31].
Second, probiotics could sequester essential nutrients from
invading pathogens and impair their colonization ability.
Third, probiotics may alter the gene expression program
of pathogens in such a way as to inhibit the expression
of virulence functions [32]. Lastly, probiotics may create
an unfavorable environment for pathogen colonization by
altering pH, the mucus layer, and other factors in the local
surroundings. It is important to note that although many of
these possible eﬀects have been demonstrated in vitro, the
ability of probiotics to exclude pathogens in vivo remains to
be proven.
2.6. Enhancingintestinalbarrierfunction
Probiotics may have strain-dependent eﬀects on the immune
system. Diﬀerent strains representing diﬀerent Lactobacil-
lus species demonstrated contrasting eﬀects with respect
to proinﬂammatory cytokine production by murine bone
marrow-derived dendritic cells [33]. Speciﬁc probiotic
strains counteracted the immunostimulatory eﬀects of other
strains so that probiotics have the potential to yield addi-
tive or antagonistic results. Interestingly, in this study,
the anti-inﬂammatory cytokine IL-10 was maintained at
similar levels [31]. Diﬀerent probiotic Lactobacillus strains
of the same species may also yield contrasting eﬀects
with respect to immunomodulation. Human breast milk-
derived Lactobacillus reuteri strains either stimulated the key
proinﬂammatory cytokine, human tumor necrosis factor
(TNF), or suppressed its production by human myeloid
cells [34]. The mechanisms of action may be due, not
surprisingly, to contrasting eﬀects on key signaling pathways
in mammalian cells. Probiotic strains such as Lactobacillus
rhamnosus GG (LGG) may activate NF-κB and the signal
transducer and activator of transcription (STAT) signaling
pathways in human macrophages [35]. In contrast, probiotic
Lactobacillus strains may suppress NF-κB signaling [36, 37]
or MAP kinase-/c-Jun-mediated signaling [34]. Stimulation
of key signaling pathways and enhancement of proinﬂam-
matory cytokine production may be important to “prime”
the immune system for defense against gastrointestinal
infections.Conversely,suppressionofimmunesignalingmay
be an important mechanism to promote homeostasis and
tolerance to microbial communities with many potential
antigens, and these immunosuppressive functions may pro-
mote healing or resolution of infections.
2.7. Whyunderstandingmechanismsisimportant?
The disruption of epithelial barrier function and loss of
tight junction formation in the intestinal epithelium may
contribute to pathophysiology and diarrheal symptoms
observed during infection with certain pathogens [38, 39].
Loss of tight junctions can lead to increased paracellular
transport that can result in ﬂuid loss and pathogen invasion
of the submucosa. Pathogens may secrete factors such
as enterotoxins that may promote excessive apoptosis or
necrosis of intestinal epithelial cells, thereby disrupting the
intestinal barrier. Enteric pathogens may also cause eﬀacing
lesions at the mucosal surface due to direct adherence
with intestinal epithelial cells (e.g., EPEC). In contrast,
probiotics have been reported to promote tight junction
formation and intestinal barrier function [40, 41]. Although
the mechanisms of promoting barrier integrity are not well
understood, probiotics may counteract the disruption of the
intestinalepithelialbarrierdespitethepresenceofpathogens.
Probiotics may also suppress toxin production or interfere
with the abilities of speciﬁc pathogens to adhere directly
to the intestinal surface. As a result, pathogens may have a
diminished ability to disrupt intestinal barrier function.
2.8. Importantconsiderationsfortheuseofprobiotics:
strainselectionandmicrobialphysiology
An important challenge in the ﬁeld of probiotics is the
identiﬁcation of genes and mechanisms responsible for the
beneﬁcial functions exerted by these microbes. Successful
identiﬁcation of mechanistic details for how probiotics
function will have at least three important beneﬁts. First,
understanding mechanisms of action will provide a scientiﬁc
basis for the beneﬁcial eﬀects provided by speciﬁc microbes.
These breakthrough investigations will help move probiotics
from the status of dietary supplements to therapeutics.
Second, understanding mechanisms of probiosis and the
gene products produced by probiotics will allow for the
identiﬁcation of more potent probiotics or the development
of bioengineered therapeutics. As an example, the anti-
inﬂammatorycytokineIL-10waspostulatedtobeapotential
therapeutic for the treatment of inﬂammatory bowel dis-
ease. To test this hypothesis, a strain of Lactococcus lactis
engineered to produce and secrete IL-10 was constructed
and demonstrated to reduce colitis in a murine model [42].
Early clinical trials in patients with inﬂammatory bowel
disease indicate some relief from symptoms when treated
withtheIL-10overproducingstrain.Third,theidentiﬁcation
ofgeneproductsthatareresponsibleforamelioratingdisease
will allow researchers, industry, and clinicians to follow
the production of these products as important biomarkers
during probiotic preparation. As discussed below, the phys-
iological state of microbes can be crucial to the functions of
probiotics. Thus, it will be important to be able to follow theR. A. Britton and J. Versalovic 5
productionofimportantbioactivemoleculeswhenculturing
and processing probiotics for applications in animals and
humans.
2.9. Probioticsanddiarrhea
Probiotics are considered to be living or viable microorgan-
isms by deﬁnition. Unlike small molecules that are stable
entities, probiotics are dynamic microorganisms and will
change gene expression patterns when exposed to diﬀerent
environmental conditions. This reality has two important
implications for those who choose to use these organisms
to combat human or animal diseases. First, probiosis is a
strain-speciﬁc phenomenon. As deﬁning a bacterial species
is challenging in this age of full genome sequencing, it
is clear that probiotic eﬀects observed in vitro and in
vivo are strain speciﬁc. For example, modulation of TNF
production by strains of Lactobacillus reuteri identiﬁed
strains that were immunostimulatory, immunoneutral, and
immunosuppressive for TNF production [34, 43]. These
ﬁndings highlight the strain-speciﬁc nature of probiotic
eﬀects exerted by bacteria. Thus, it is important for research
groups and industry to be cautious with strain handling and
tracking so that inclusion of correct strains is veriﬁed prior
to administration in clinical trials.
The second key point is that the physiology of the
probiotic strain is an important consideration. Being live
microorganisms, the proteins and secondary metabolites
that are being produced will change depending on growth
phase. This feature raises a number of important issues for
the stability and eﬃcacy of probiotic strains. First, probiotics
are subjected to numerous environmental stresses during
production and after ingestion by the host. Most notably,
probiotics used to treat intestinal ailments or whose mode of
action is thought to be exerted in the intestinal tract must
be able to survive both acid and bile stress during transit
through the gut. The physiological state of the microbe is an
importantcharacteristicthatdetermineswhethercellswillbe
susceptibletodiﬀerenttypesofenvironmentalstress[44,45].
For example, exponentially growing cells of L. reuteri are
much more susceptible to killing by bile salts than cells in
stationary phase [45]. Thus, it is important to consider the
physiological state of the cells in terms of stress adaptation
not only for survival in the host but also during production.
Second, the expression of bioactive molecules, which are
most often responsible for the health beneﬁts exerted by
probiotics, is often growth phase-dependent. For example,
our groups have been investigating the production of
immunomodulatory compounds and antimicrobial agents
by strains of L. reuteri. In both cases, these compounds are
morehighlyexpressedintheentryintoandduringstationary
phase (unpublished observation).
3. PROBIOTICS AND THE PREVENTION AND
TREATMENT OF GASTROENTERITIS—EXAMPLES
Commensal-derived probiotic bacteria have been implicated
as therapy for a range of digestive diseases, including
antibiotic-associated colitis, Helicobacter pylori gastritis, and
traveler’s diarrhea [46]. Probiotic formulations may include
single strains or combinations of strains. L. reuteri is
indigenous to the human gastrointestinal tract, is widely
present in mammals, and has never been shown to cause
disease. In human trials, probiotic treatment with L. reuteri
in small children with rotaviral gastroenteritis reduced the
duration of disease and facilitated patient recovery [15, 16],
while in another study, it prevented diarrhea in infants [17].
Despite the promising data from clinical trials, the primary
molecular mechanisms underlying the antipathogenic prop-
erties of L. reuteri remain unknown.
Probiotics may be eﬀective for the prevention or
treatment of infectious gastroenteritis. In the context of
disease prevention, several studies with diﬀerent probiotic
strains have documented that these bacteria may reduce the
incidence of acute diarrhea by 15–75% depending on the
study [17, 47–50]. Although the relative impacts on disease
incidencevarydependingonthespeciﬁcprobioticstrainand
patientpopulation, consistentbeneﬁtsfordiseaseprevention
have been demonstrated in multiple clinical studies. In
one disease prevention study [49], supplementation with
Biﬁdobacterium lactis signiﬁcantly reduced the incidence of
acute diarrhea and rotavirus shedding in infants. Studies
that examined potential beneﬁts of probiotics for preventing
antimicrobial-associated diarrhea have yielded mixed results
[51–54]. One prevention study reported a reduction in
incidence of antimicrobial-associated diarrhea in infants by
48% [52].
Probiotics may also be incorporated in treatment reg-
imens for infectious gastroenteritis. Several meta-analyses
of numerous clinical trials with diﬀerent probiotics docu-
mented reductions in disease course of gastroenteritis that
ranged from 17 to 30 hours [49, 50, 55]. Examined another
way, meta-analyses of probiotics used in clinical trials of
gastroenteritis noted signiﬁcant reductions of incidence of
diarrhealastinglongerthan3days(prolongeddiarrhea).The
incidence of prolonged diarrhea was diminished by 30% or
60%, respectively, depending on the study [50, 56]( s u m -
marized in [55]). The probiotic agent, LGG, contributed
to a signiﬁcant reduction in rotavirus diarrhea by 3 days
of treatment when administered to children as part of oral
rehydration therapy [57]. Recent data compilations of a
large series of probiotics trials by the Cochrane Database of
Systematic Reviews (http://www.cochrane.org/)h a v ey i e l d e d
promising conclusions. As of 2008, probiotics appear to
be eﬀective for preventing acute gastroenteritis in children
and may reduce duration of acute disease. Additionally,
probiotics are promising agents for preventing and treating
antimicrobial-associated diarrhea, although intention-to-
treat analyses have not demonstrated beneﬁts.
3.1. Clostridiumdifﬁcileand
antibiotic-associateddiarrhea
In what follows, we highlight some possible mechanisms by
which probiotics can be used to ameliorate gastroenteritis.
Because a number of infectious agents cause diarrhea, colitis,
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with the idea that many of the mechanisms discussed can be
extended to other bacterial or viral causes of diarrhea.
3.1.1. ThepotentialroleofprobioticsintreatingCDAD
An estimated 500,000–3,000,000 cases of Clostridium
diﬃcile-associated diarrhea (CDAD) occur annually with
related health care costs exceeding $1 billion per year [58–
60]. CDAD occurs primarily in patients that have undergone
antibiotic therapy in a health care setting, indicating that
alterations in the intestinal microbiota are important for
the initiation of CDAD. In a small but increasing number
of cases, more severe complications will occur including
pseudomembranous colitis and toxic megacolon. Moreover,
the emergence of metronidazole-resistant strains of C.
diﬃcile has diminished the eﬃcacy of metronidazole, and
vancomycin- and metronidazole-induced cecitis reinforces
the need for new therapies for the treatment and prevention
of CDAD [61, 62].
Approximately 10–40% of patients treated for an initial
bout of CDAD will show recurrent disease, often with
multiple episodes [63]. Such recurrences are often refractory
to existing therapies including antibiotic therapy. Patients
with recurrent CDAD had a marked decrease in the diversity
of organisms in their fecal microbiota while patients that
were free of recurrent disease had a normal microbiota [64].
Thus, therapies that restore a normal microbiota or suppress
C. diﬃcile growth while allowing the repopulation of the
intestine with a favorable microbiota may be important to
resolve infections and maintain intestinal health.
3.1.2. EradicationofC.difﬁcilethroughtheproductionof
antimicrobialcompounds
Probiotic organisms have been used to treat recurrent C.
diﬃcile in the past and in a few cases have showed a modest
eﬀectinamelioratingrecurrentdisease[63].Thisapplication
has been somewhat controversial and at this time the use of
probiotics in ameliorating CDAD is not recommended [65].
However, the organisms tested were not speciﬁcally isolated
for the treatment of CDAD and, therefore, may have not
been the appropriate strains to be used to prevent recurrent
CDAD. In what follows, we outline potential mechanisms in
which carefully selected or engineered probiotics could be
used in the treatment of C. diﬃcile and the eradication of
this pathogen.
3.1.3. CompetitiveexclusionofC.difﬁcile
usingprobiotics
CDAD is currently treated by the use of antimicrobial agents
that are eﬀective against C. diﬃcile, most often vancomycin
or metranidazole. Because these drugs are broad-spectrum
antibiotics, they likely play a role in recurrent disease by
suppressing the normal intestinal microbiota. Using antimi-
crobial compounds that target C. diﬃcile while allowing
restoration of resident organisms would be one possible
mechanism to prevent recurrent CDAD.
3.1.4. ProbioticsandC.difﬁcilesporegermination
As mentioned above, CDAD is usually an infection that is
acquired in the hospital or other health care setting.
Therefore, a probiotic that could competitively exclude
C. diﬃcile could be administered prior to entry into the
hospital. Unfortunately, little is known about how and where
C. diﬃcile colonizes the intestine. Once this information is
known, strategies for blocking colonization with probiotics
can be developed.
Nonetheless, a promising probiotic approach using non-
toxigenic C. diﬃcile has been described. Using a hamster
model of C. diﬃcile infection, Gerding et al. demonstrated
ap r o t e c t i v ee ﬀect of populating the hamster with strains
of C. diﬃcile that are unable to produce toxin prior
to challenge with a virulent toxin-producing strain [66].
Colonization of the intestinal tract by the nontoxigenic
strain appeared to be required for protection. Currently, this
probiotic approach is under investigation for use in humans
(http://www.viropharma.com/).
3.2. EnterohemorrhagicE.coli
A likely contributor to the diﬃculty in eradicating C. diﬃcile
from the intestine is the ability of the organism to develop
stress-resistant spores. The identiﬁcation of probiotic strains
that can prevent either spore formation or the germination
of spores in the intestinal tract provides a promising avenue
to combat CDAD. Recent work on spore germination has
provided in vitro assays in which inhibitory activities of
probiotics can be tested [67].
Germination of spores in the laboratory requires the
presence of bile acids, with taurocholate and cholate demon-
strating the best activity [67]. Thus, bile acids could play a
role in signaling to C. diﬃcile that spores are in the correct
location of the gut to germinate. Sorg and Sonenshein have
recently proposed a mechanism by which the reduction in
the intestinal microbiota could lead to eﬃcient spore germi-
nation and overgrowth of C. diﬃcile [67]. They found that
the bile acid deoxycholate (DOC) was able to induce spore
germination but that subsequent growth was inhibited due
to toxic eﬀects of DOC on vegetative C. diﬃcile.T h e i rw o r k
suggests a model in which a reduction in the concentration
of DOC in the intestine, due to the disruption of the normal
microbiota, removes this key inhibitor of C. diﬃcile growth.
DOCisasecondarybileacidproducedfromdehydroxylation
of cholate by the enzyme 7α-dehydroxylase, an activity that
is produced by members of the intestinal microbiota. While
it is unclear whether or not antibiotic therapy reduces the
level of DOC in the intestine, it is tempting to speculate
that providing probiotic bacteria capable of producing 7α-
dehydroxylase may prevent intestinal overgrowth by C.
diﬃcile while the normal microbiota is being reestablished.
3.2.1. Toxinsequestrationandremoval
Enterohemorrhagic E. coli (EHEC) infections cause sporadic
outbreaks of hemorrhagic colitis throughout the world
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infections result in the development of bloody diarrhea but
as u b s e t( ∼5–10%) of EHEC patients (mostly children)
will develop the life-threatening condition hemolytic uremic
syndrome (HUS) [69, 70]. HUS is the leading cause of
kidney failure in children. EHEC, which likely evolved
from an EPEC strain [71], also produces attaching and
eﬀacing lesions on host epithelial cells and reduces intestinal
epithelial barrier function. In addition, EHEC strains are
characterized by the expression of Shiga toxin (Stx) genes,
and thus they can be labeled as Shiga-toxin-producing E.
coli (STEC). Currently, only supportive therapy for EHEC
infection is available since antibiotic therapy may increase
the risk of developing HUS, and therefore, novel therapies
must be developed. One promising alternative therapeutic
may be the use of probiotics to treat EHEC infections.
3.2.2. Inhibitionoftoxinproductionby
EHEC—identiﬁcationofstrainsthat
repressthelyticfunctionsoflambda
Shiga toxins are ribosome-inactivating proteins that inhibit
protein synthesis by removing a speciﬁc adenine residue
from the 28S rRNA of the large ribosomal subunit [72].
Shiga toxin is required for the development of HUS and
recent work has indicated that EHEC strains mutated for
Shiga toxin production fail to cause disease in a germfree
mouse model [73]. Indeed, injection of Shiga toxin with
LPS directly into mice is suﬃcient to generate a HUS-like
disease in the kidneys of mice [74]. Therefore, Shiga toxin
is an important mediator of HUS and therapies aimed at
neutralizing its activity are expected to reduce or eliminate
this life-threatening complication although current attempts
at Shiga toxin neutralization have been unsuccessful [75].
As a possible mechanism for treating EHEC disease and
reducing the incidence of HUS cases, Paton et al. have
generated “designer probiotics” in which the oligosaccharide
receptor (Gb3) for Stx is expressed on the cell surface
of an E. coli strain [76–78]. This probiotic strain was
shown to be capable of neutralizing Stx in vitro. As a
proof-of-concept, mice that were challenged with a STEC
strain were protected by administration of the probiotic
expressing the Gb3 receptor [79] .T h ep r o t e c t i v ee ﬀect was
observed even when the strains were formalin-killed prior
to use, supporting the hypothesis that toxin sequestration
and removal was the mechanism by which the mice were
protected. Similar results have been obtained using bacteria-
expressing receptors for toxins produced by other diarrheal
pathogens including enterotoxigenic E. coli (most common
cause of traveler’s diarrhea) and Vibrio cholerae.
3.2.3. Inhibitionofpathogenadherenceandstrengthening
ofintestinalbarrierfunctions
Stx genes are carried on lambdoid prophages and are usually
located in a late transcribed region of the virus, near the lytic
genes [80]. Since no mechanism for toxin secretion has been
identiﬁed, the location of Stx near the lytic genes suggests
that phage activation and cell lysis are responsible for Stx
production and release. This genetic juxtaposition suggests
thattherapeuticsthatsuppressthelyticdecisionoflambdain
vivo would greatly reduce or eliminate complications caused
by systemic release of Stx.
3.3. Rotavirus
Ak e yi n t e r a c t i o no fE H E C ,a sw e l la sE P E C ,w i t ht h e
intestinal epithelium is the formation of attaching and
eﬀacing lesions on the surface of the epithelium [81]. This
interaction is brought about by factors secreted directly from
the bacterium into the host cell, where a redistribution of
theactincytoskeletonoccurs.EHECandEPECinfectionalso
induces a loss of tight junction formation and reduction of
the intestinal epithelial barrier by inducing the rearrange-
ment of key tight junction proteins including occludin [82,
83]. Therapies that would either disrupt this interaction of
EHEC/EPECwiththeintestinalepitheliumorinhibittheloss
of barrier function should ameliorate disease.
Probiotics have shown some success inhibiting adhesion,
A/E lesion formation and enhancing barrier function in
response to EHEC infection in vitro. Johnson-Henry et al.
tested the ability of Lactobacillus rhamnosus GG to prevent
lossofbarrier integrity andformationofA/Elesionsinduced
by EHEC infection of cell culture in vitro [40]. They
found that pretreatment of intestinal epithelial cells in vitro
with LGG was suﬃcient to reduce the number of A/E
lesions and to prevent loss of barrier function as measured
by transepithelial resistance, localization of tight junction
proteins, and barrier permeability assays. Importantly, live
LGG was required for these eﬀects as heat-killed bacteria
were not eﬀective in preventing EHEC eﬀects on epithelial
cells.
Enteric viruses including noroviruses and rotavirus rep-
resent major causes of gastroenteritis, especially in young
children. Rotavirus infection results in acute gastroenteritis
with accompanying dehydration and vomiting mainly in
children 3–24 months of age. Human rotavirus primarily
infects intestinal epithelial cells of the distal small intestine,
resulting in enterotoxin-mediated damage to intestinal bar-
rier function. Recent studies indicate that probiotics may
reduce the duration and ameliorate disease due to rotavirus
infection ([84]; G. Preidis and J. Versalovic, unpublished
data). Probiotics promoted intestinal immunoglobulin pro-
duction and appeared to reduce the severity of intestinal
lesions due to rotavirus infection in a mouse model. These
ﬁndings and related investigations suggest that probiotics
may diminish the severity and duration of gastrointestinal
infections by mechanisms independent of direct pathogen
antagonism.Probioticsmayalsopromotehealingandhome-
ostasis by modulating cytokine production and facilitating
intestinal barrier function.
4. CONCLUDING REMARKS
Probiotics may provide an important strategy for the pre-
vention and treatment of gastrointestinal infections. Speciﬁc
bacteria derived from human microbial communities may
have key features that establish these microbes as primary
candidates for probiotic therapies. These beneﬁcial microbes8 Interdisciplinary Perspectives on Infectious Diseases
may have diﬀerent eﬀects within the host such as prevention
of pathogen proliferation and function. Probiotics may
also stimulate the host’s immune function and mucosal
barrier integrity. By working via diﬀerent mechanisms of
probiosis, probiotics may yield eﬀects at diﬀerent steps in the
process.Probioticsmaypreventdiseasefromoccurringwhen
administered prophylactically. Probiotics may also suppress
or diminish severity or duration of disease in the context
of treatment. As our knowledge of the human microbiome
advances, rational selection of probiotics based on known
mechanisms of action and mechanisms of disease will facil-
itate optimization of strategies in therapeutic microbiology.
Ultimately, we expect that probiotics will help to promote
stable, diverse, and beneﬁcial microbial communities that
enhance human health and prevent disease.
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